TX-MARY-KAY
4.11.2021 13:14:11 CET | Business Wire | Press release
Mary Kay Inc., a leading corporate advocate of women’s empowerment and entrepreneurship, announced today its second World Series of Innovation (WSI) Challenge in partnership with Network for Teaching Entrepreneurship (NFTE). In its second year partnering with NFTE, Mary Kay is sponsoring the 2021 NFTE World Series of Innovation, a global educational experience that invites young people ages 13-24 to channel their critical thinking and problem-solving skills to find solutions for the biggest challenges facing the world today and help advance the UN Sustainable Development Goals (SDGs) while fostering an entrepreneurial mindset.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005178/en/
Mary Kay’s World Series of Innovation Challenge encourages young people from around the world to submit innovative solutions to address Sustainable Development Goal 5: Gender Equality . Specifically, this challenge asks students to think about ways to promote workplace equality and ensure equal access to economic opportunity for women and girls. Pre-Covid, decades of data demonstrated the rise of women in the workforce -even though the wage gap persisted - more women were joining the labor market every year. But pandemic job losses disproportionately impacted women, and since 2020, the uphill climb to workforce equality has grown even steeper.
“Mary Kay knows the importance of entrepreneurship and the role it plays in the world today and in the future, which is why we invest annually in programs and initiatives to help empower women and girls around the world,” said Deborah Gibbins, Chief Operating Officer for Mary Kay Inc. “We want to help not only provide educational opportunities but help them pursue their dreams around the world. We are beyond excited for this challenge so connected to our company’s core mission.”
NFTE is a global educational nonprofit focused on bringing the power of entrepreneurship to youth in low-income communities. The World Series of Innovation (WSI) Challenge invites corporate sponsored challenges to address the UN Sustainable Development Goals. With a reach of 100,000 students worldwide, in 2020, NFTE received nearly 4,000 student participants of all backgrounds submitting ideas in the WSI Challenges and nearly 350 students participated in the first-ever Mary Kay-sponsored challenge to address Sustainable Development Goal 12: Responsible Consumption and Production. The three winners of Mary Kay’s 2020 Challenge were:
-
First Place: Loop Tee Loop
- Loop Tee Loop is a sustainable clothing loop uniting lyocell textile mills with uniform recycling collection services from Metro Manila in the Philippines.
-
Second Place: SwagSwap
- SwagSwap is a US-based social network for thrifting, enabling peer-to-peer clothing swap for teens.
-
Third Place: Project DBrand
- Project DBrand is a unique service that de-brands used uniforms so they can be upcycled based in the US.
“Supporting the entrepreneurial development of young people is critical to help build a better world for future generations,” said J.D. LaRock, President and Chief Executive Officer of NFTE. “Each year, we continue to be inspired by the innovations the next generation of entrepreneurs envision, and we look forward to seeing all the new ideas from WSI competitors in 2021. We are grateful to Mary Kay Inc. for its support for the second year posing this critical global challenge to help advance workplace equality and achieve equal access to economic opportunity for women and girls.”
In addition to the World Series of Innovation, Mary Kay supported NFTE’s Entrepreneurship in Every School program, bringing the entrepreneurial journey through curriculum to students across the U.S. and internationally; and sponsored NFTE’s Regional Youth Entrepreneurship Challenges where students pitch business opportunities for seed money in a competitive setting.
The 2021 NFTE World Series of Innovation is presented by Citi Foundation and features challenges from Bank of the West, Citi Foundation, Ernst & Young LLP (EY US), Mary Kay, Inc., Maxar Technologies, PIMCO, and Saint-Gobain. Challenges launched on September 15th and entries are due by December 15th . Judging begins in January of 2022. Finalists will be announced in February and winners will be announced on March 31st .
For more information about the World Series of Innovation and all challenges, visit https://innovation.nfte.com
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more about Mary Kay at www.marykayglobal.com
About NFTE
Network for Teaching Entrepreneurship (NFTE) is a global nonprofit organization that provides high-quality entrepreneurship education to middle and high school students from under-resourced communities, as well as programs for college students and adults. NFTE will reach 45,000 students this academic year, with programs in 25 states across the U.S. and in 20 additional countries. Since our founding, we have educated more than a million students through in-school, out-of-school, college, and summer camp programs, offered in person and online. To learn more about how we are promoting inclusive capitalism and building the next generation of diverse entrepreneurs, visit www.nfte.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005178/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
